ArticleCell research2020
Transferrin plays a central role in coagulation balance by interacting with clotting factors.
Article in Cell research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Pooled it
- Article
- Angiotensin II exacerbates intracerebral hemorrhage in mice via heparin-like antithrombin activation and coagulation dysfunction.Nature communications · 2026Article
- KDIGO 2026 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP).Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Article
- Inhibiting thromboinflammation with a designed peptide that blocks the IL-1β-FXIa axis uncouples antithrombosis from bleeding risk.Cellular and molecular life sciences : CMLS · 2026Article
- Low serum transferrin predicts adverse outcome in COVID-19 and is related to coagulation activity.British journal of haematology · 2026Article
- Real-world use of HIF-PH inhibitors in the Japan dialysis and practice patterns study (J-DOPPS, 2019-2022).BMC nephrology · 2026Article
- Mevalonic acid exerts procoagulant effect by potentiating factor Xa.Natural products and bioprospecting · 2026Article
- Activation of the coagulation cascade as a mechanism for selective nanoparticle-mediated RNA delivery to the endothelium in vivo.Science advances · 2025Article
- High-fat diet increases circulating palmitic acid produced by gut Bacteroides thetaiotaomicron to promote thrombosis.Cell reports. Medicine · 2025Article
- Identification of Plasma Free Fatty Acid Carrier Proteins in Mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Exploring Plasma Proteome Thermal Stability in Peripheral Arterial Disease: Biophysical Findings Under Cilostazol Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Essential and Non-Essential Metals and Metalloids and Their Role in Atherosclerosis.Cardiovascular toxicology · 2025Review
- Increased Transferrin Concentrations Are Not Associated With Thrombosis in People Living at High Altitude.Journal of hematology · 2025Article
- Transferrin Disassociates TCR from CD3 Signaling Apparatus to Promote Metastasis.Research (Washington, D.C.) · 2025Article
- Machine learning-based preoperative prediction of perioperative venous thromboembolism in Chinese lung cancer patients: a retrospective cohort study.Frontiers in oncology · 2025Article
- The Role of Iron in Atherosclerosis and its Association with Related Diseases.Current atherosclerosis reports · 2024Review
- ShSPI Inhibits Thrombosis Formation and Ischemic Stroke In Vivo.International journal of molecular sciences · 2024Article
- Cancer progression and tumor hypercoagulability: a platelet perspective.Journal of thrombosis and thrombolysis · 2024Review
- T-cell Immunoglobulin and Mucin Domain 3 in Circulating Monocytes as a Novel Biomarker for Coronary Artery Disease.Journal of cardiovascular translational research · 2024Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coagulation balance is maintained through fine-tuned interactions among clotting factors, whose physiological concentrations vary substantially. In particular, the concentrations of coagulation proteases (pM to nM) are much lower than their natural inactivator antithrombin (AT, ~ 3 μM), suggesting the existence of other coordinators. In the current study, we found that transferrin (normal plasma concentration ~40 μM) interacts with fibrinogen, thrombin, factor XIIa (FXIIa), and AT with different affinity to maintain coagulation balance. Normally, transferrin is sequestered by binding with fibrinogen (normal plasma concentration ~10 μM) at a molar ratio of 4:1. In atherosclerosis, abnormally up-regulated transferrin interacts with and potentiates thrombin/FXIIa and blocks AT's inactivation effect on coagulation proteases by binding to AT, thus inducing hypercoagulability. In the mouse model, transferrin overexpression aggravated atherosclerosis, whereas transferrin inhibition via shRNA knockdown or treatment with anti-transferrin antibody or designed peptides interfering with transferrin-thrombin/FXIIa interactions alleviated atherosclerosis. Collectively, these findings identify that transferrin is an important clotting regulator and an adjuster in the maintenance of coagulation balance and modifies the coagulation cascade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.